← All trials
NCT02658253
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2016
- Primary completion
- Apr 1, 2017
- Completion date
- Apr 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 68
- Arms / groups
- 10 / —
- Source
- AACT · pre-existing
Sponsors
- Institut National de la Santé Et de la Recherche Médicale, FranceLead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceStudy director
- Institut National de la Santé Et de la Recherche Médicale, FranceStudy chair
- EUCLIDCollaborator
- University of ParisCollaborator
- Centre National de Recherche et de Formation sur la Paludisme, Ouagadougou, Burkina FasoStudy chair
- Centre National de Recherche et de Formation sur la Paludisme, Ouagadougou, Burkina FasoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.